Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Bone Cancer
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
Chemotherapy-Stimulated Immune Response: An Open Debate
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.
FDA Calls for Patient Registries to Track Robotically Treated Cancers
Head-to-head comparisons of these types of surgical interventions are still needed, according to the regulatory body.
Drug Shortages Threaten Childhood Cancer Treatment
Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.
Study Finds Shortage of Medical Geneticists
How will oncology deal with a lack of medical genetics professionals to help treat cancer with precision genomic medicine?
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cancer Topics, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Endocrine Cancer, Gastrointestinal Cancers, General Oncology, Gynecologic Cancer, Head and Neck Cancer, Hematologic Cancers, Lung Cancer, Lymphoma, Multiple Myeloma, Pancreatic Cancer, Pediatric Cancer, Prostate Cancer, Renal Cell Carcinoma, Sarcoma, Skin Cancer, Urologic Cancers
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%…
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Next post in General Oncology
